dr. petrylak on the keynote-045 trial for urothelial carcinoma
Published 7 years ago • 61 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
1:05
dr. petrylak on combinations with pembrolizumab in urothelial carcinoma
-
1:40
dr. petrylak on trial of atezolizumab in urothelial carcinoma
-
1:18
dr. plimack on keynote-045 trial for pembrolizumab in urothelial carcinoma
-
1:45
dr. rosenberg on the keynote-045 trial in advanced urothelial cancer
-
2:03
dr. petrylak on enfortumab vedotin in locally advanced or metastatic urothelial carcinoma
-
0:38
dr. petrylak on fda approval of pembrolizumab in bladder cancer
-
0:50
dr. petrylak on atezolizumab in bladder cancer
-
56:27
ccf webinar: a clinical trial for a potential new ther2apy for biliary tract cancers
-
1:07
dr. petrylak on the results of the ev-103 trial in bladder cancer
-
1:06
dr. daniel petrylak on early trials for a new urothelial bladder cancer treatment
-
0:58
significance of keynote-045 trial of pembrolizumab vs chemotherapy in urothelial carcinoma
-
1:01
dr. petrylak on novel immunotherapy research in bladder cancer
-
1:08
dr. petrylak on the future immunotherapy in bladder cancer
-
0:57
dr. petrylak on immunotherapy in bladder cancer
-
1:47
dr. petrylak on sequencing of targeted agents in bladder cancer
-
1:29
dr. daniel petrylak on the imvigor study of atezolizumab in advanced bladder cancer
-
0:37
dr. petrylak on fda approval of nivolumab in bladder cancer
-
0:34
dr. petrylak discusses custirsen as a potential treatment for prostate cancer
-
1:41
dr. petrylak on immunotherapy for second-line treatment in bladder cancer